michigan glp-1 constipation law firm Patients struggle as compounded access rapidly shrinks As GLP-1 drugs continue to
Description
Each author engaged in writing original content, reviewing, and editing subsequent versions of the submission and all authors approved the final draft
Table 6 summarizes the adverse reactions that occurred in 2 or more IMCIVREE-treated patients in Trial 2 during the 52-week active treatment period
list price as of April 2026 (Novo Nordisk published pricing) as of April 2026
Regarding adverse effects, more participants receiving once-weekly exenatide experienced injection site pruritus, while treatment-related nausea and vomiting were more frequent in the twice-daily exenatide group
